Anzeige
Meldung des Tages: Unter dem Radar, voll finanziert: Beginnt jetzt der nächste Gold-Run?

Immunic News

Aktie
WKN:  A2PHD4 ISIN:  US4525EP1011 US-Symbol:  IMUX Branche:  Biotechnologie Land:  USA
1,045 €
+0,00 €
0,00%
16:30:10 Uhr
Depot/Watchlist
Marktkapitalisierung *
47,04 Mio. €
Streubesitz
61,15%
KGV
-0,79
Index-Zuordnung
-

Immunic News

09.04.26 - EQS
EQS-News: Immunic to Participate in Scientific and Medical Conferences in April
Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Scientific and Medical Conferences in April 09.04.2026 / 12:30 CET/CEST The issuer is solely responsible ...
09.04.26 - PR Newswire
Immunic to Participate in Scientific and Medical Conferences in April
Immunic to Participate in Scientific and Medical Conferences in April PR Newswire
01.04.26 - EQS
EQS-News: Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
Issuer: Immunic AG / Key word(s): Miscellaneous Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement 01.04.2026 / 12:30 CET/CEST The issuer is solely ...
01.04.26 - PR Newswire
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire
31.03.26 - EQS
EQS-News: Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
Issuer: Immunic AG / Key word(s): Personnel Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton 31.03.2026 ...
31.03.26 - PR Newswire
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton PR Newswire
10.03.26 - EQS
EQS-News: Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
Issuer: Immunic AG / Key word(s): Patent Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium 10.03.2026 / 11:30 ...
10.03.26 - PR Newswire
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium PR Newswire
03.03.26 - EQS
EQS-News: Immunic to Participate in Investor Conferences in March
Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Investor Conferences in March 03.03.2026 / 12:30 CET/CEST The issuer is solely responsible for the ...
03.03.26 - PR Newswire
Immunic to Participate in Investor Conferences in March
Immunic to Participate in Investor Conferences in March PR Newswire
26.02.26 - EQS
EQS-News: Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
Issuer: Immunic AG / Key word(s): Annual Results Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update 26.02.2026 / 12:30 CET/CEST The ...
26.02.26 - PR Newswire
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update PR Newswire
17.02.26 - EQS
EQS-News: Immunic Announces Closing of Oversubscribed Private Placement Financing
Issuer: Immunic AG / Key word(s): Financing Immunic Announces Closing of Oversubscribed Private Placement Financing 17.02.2026 / 22:05 CET/CEST The issuer is solely ...
17.02.26 - PR Newswire
Immunic Announces Closing of Oversubscribed Private Placement Financing
Immunic Announces Closing of Oversubscribed Private Placement Financing PR Newswire
13.02.26 - EQS
EQS-News: Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
Issuer: Immunic AG / Key word(s): Financing Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-​Stage ...
13.02.26 - PR Newswire
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-​Stage Company PR Newswire
04.02.26 - EQS
EQS-News: Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Issuer: Immunic AG / Key word(s): Conference/Study results Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, ...
04.02.26 - PR Newswire
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis PR ...
07.01.26 - EQS
EQS-News: Immunic Highlights 2025 Accomplishments and Upcoming Milestones
Issuer: Immunic AG / Key word(s): Miscellaneous/Conference Immunic Highlights 2025 Accomplishments and Upcoming Milestones 07.01.2026 / 12:30 CET/CEST The issuer is ...
07.01.26 - PR Newswire
Immunic Highlights 2025 Accomplishments and Upcoming Milestones
Immunic Highlights 2025 Accomplishments and Upcoming Milestones PR Newswire

Newssuche

Videos

newspaper
07.04.26 +5,59%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »